Local Excision After Preoperative Chemoradiotherapy for Rectal Cancer
Authors:
- Salvatore PucciarelliSPSalvatore Pucciarelli
- Antonino De PaoliAntonino De Paoli
- Mario GuerrieriMGMario Guerrieri
- Giuseppe La TorreGiuseppe La Torre
- Isacco MarettoIMIsacco Maretto
- Francesco De MarchiFMFrancesco De Marchi
- Giovanna MantelloGMGiovanna Mantello
- Maria Antonietta GambacortaMGMaria Antonietta Gambacorta
- Vincenzo CanzonieriVincenzo Canzonieri
- Donato NittiDNDonato Nitti
- Vincenzo ValentiniVVVincenzo Valentini
- Claudio CocoCCClaudio Coco
- 1 December 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 56 (12) , 1349-1356
Abstract
Transanal local excision has been suggested as an attractive approach for patients with rectal cancer who show a major clinical response after preoperative chemoradiotherapy. To evaluate the impact of transanal local excision on the local recurrence of rectal cancer in patients who had a major clinical response after preoperative chemoradiotherapy. Sequential 2-stage phase II study for early efficacy. Multicenter study. Patients with clinical T3 or low-lying T2 rectal adenocarcinoma that showed a major clinical response after a preoperative chemoradiotherapy. Eligible patients underwent a full-thickness transanal local excision. According to their histopathology, the patients staged as ypT0-1 were observed, while the remaining patients were recommended to undergo a subsequent total mesorectal excision. A local recurrence rate of ≤5% was set as a successful rate for stopping the trial early after the first stage. The study group included 63 patients. Before chemoradiotherapy, patients were staged as clinical T3 (n = 42) and T2 (n = 21). After the local excision, 43 patients fulfilled the criteria to be observed with no further treatment. Nine of the remaining 20 patients for whom a subsequent total mesorectal excision was recommended refused surgery. Two of these patients who refused surgery had intraluminal local recurrence; both had a ypT2 tumor and underwent salvage surgery. The estimated cumulative 3-year overall survival, disease-free survival and local disease-free survival were 91.5% (95% CI: 75.9–97.2), 91.0% (95% CI: 77.0–96.6) and 96.9% (95% CI: 80.3–99.5), respectively. The time of follow-up is still short and the sample size is limited. Our data suggest that local excision is a good option for patients with a major clinical response after chemoradiotherapy. A longer period of follow-up is required to confirm these findings.Keywords
This publication has 35 references indexed in Scilit:
- Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal CancerJournal of Clinical Oncology, 2012
- Long-term Follow-up Features on Rectal MRI During a Wait-and-See Approach After a Clinical Complete Response in Patients With Rectal Cancer Treated With ChemoradiotherapyDiseases of the Colon & Rectum, 2011
- Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiationCancer, 2011
- Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imagingRadiotherapy and Oncology, 2011
- Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trialsContemporary Clinical Trials, 2010
- Local Excision After Preoperative Chemoradiation Results in an Equivalent Outcome to Total Mesorectal Excision in Selected Patients with T3 Rectal CancerAnnals of Surgical Oncology, 2009
- A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapySurgical Endoscopy, 2007
- Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203Journal of Clinical Oncology, 2006
- Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapyColorectal Disease, 2006
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989